Yan Xi, Han Lina, Zhao Riyang, Fatima Sumaya, Zhao Lianmei, Gao Feng
Department of Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Heliyon. 2022 Jul 13;8(8):e09953. doi: 10.1016/j.heliyon.2022.e09953. eCollection 2022 Aug.
Interleukins are assumed to be closely related to the occurrence and development of human malignant tumors, while a few of them were commonly used as diagnostic markers in clinical cancer, including lung cancer. This study aimed to explore the value of serum interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-8 (IL-8) combined with carcinoembryonic antigen (CEA) as biomarker panel for the diagnosis and metastasis prediction of lung cancer. IL-1β, IL-6, IL-8, and CEA in serum were determined using electrochemiluminescence immunoassay (ECLIA) and flow cytometry, and the diagnostic value of each marker was analyzed using receiver operating characteristic (ROC) curves and logistic fitting regression. We found that the levels of serum IL-1β, IL-6, and IL-8 showed no significant difference among squamous cell carcinoma, adenocarcinoma, and small cell carcinoma, while they were significantly higher in the lung cancer group or benign group than those in the healthy group. The levels of IL-8 and CEA were positively correlated with clinical stages respectively. Importantly, the panel of CEA + IL-6 + IL-8 has the highest efficacy for the diagnosis of lung cancer (AUC = 0.883) among all the detected panels, while the panel of IL-8 + CEA showed the most promising predictive value for the lymph node metastasis (AUC = 0.686) and distant metastasis of lung cancer (AUC = 0.793). In conclusion, IL-6 and IL-8 could be used as promising molecular biomarkers to diagnose and predict the metastasis of lung cancer independent of pathological types, improving the specificity and sensitivity of diagnosis for lung cancer when they were combined with CEA.
白细胞介素被认为与人类恶性肿瘤的发生和发展密切相关，而其中一些白细胞介素在临床癌症（包括肺癌）中常用作诊断标志物。本研究旨在探讨血清白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）和白细胞介素-8（IL-8）联合癌胚抗原（CEA）作为生物标志物组合在肺癌诊断和转移预测中的价值。采用电化学发光免疫分析法（ECLIA）和流式细胞术测定血清中的IL-1β、IL-6、IL-8和CEA，并使用受试者工作特征（ROC）曲线和逻辑拟合回归分析每个标志物的诊断价值。我们发现，血清IL-1β、IL-6和IL-8水平在鳞状细胞癌、腺癌和小细胞癌之间无显著差异，但在肺癌组或良性组中显著高于健康组。IL-8和CEA水平分别与临床分期呈正相关。重要的是，在所有检测的组合中，CEA + IL-6 + IL-8组合对肺癌的诊断效能最高（AUC = 0.883），而IL-8 + CEA组合对肺癌淋巴结转移（AUC = 0.686）和远处转移（AUC = 0.793）显示出最有前景的预测价值。总之，IL-6和IL-8可作为有前景的分子生物标志物，独立于病理类型诊断和预测肺癌转移，与CEA联合使用时可提高肺癌诊断的特异性和敏感性。
